Bicara Therapeutics Inc.
BCAX Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$17.48
KIRA · Stoqly’s AI analyst, in plain words
- Bicara Therapeutics Inc. lost $138M in fiscal 2025.
- Free cash flow was −$107M in fiscal 2025, — of revenue.
Market cap
$1.2B
P/E
—
Revenue
—
Net income
−$138M
Free cash flow
−$107M
Operating margin
—
Bicara Therapeutics Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$138M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Bicara Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Bicara Therapeutics Inc.
- CIK
- 0002023658
Bicara Therapeutics Inc. · BCAX
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$52.0M | −$68.0M | −$138M |
| Diluted EPS | −$89.61 | −$4.05 | −$2.52 |
| Cash | |||
| Cash from operations | −$45.6M | −$74.8M | −$107M |
| Capital expenditure | $0.6M | $0.1M | $0.3M |
| Free cash flow | −$46.2M | −$74.8M | −$107M |
| Share count change | — | 2,797.0% | 225.4% |
| Debt and strength | |||
| Cash and short-term investments | $230M | $490M | $415M |
| Shareholders' equity | −$149M | $492M | $401M |
| Current ratio | 15.3x | 27.9x | 14.6x |
| Returns and quality | |||
| Return on equity | — | −39.6% | −30.9% |
| Return on tangible equity | — | −13.8% | −34.4% |
| Altman Z'' | −7.3 | 32.2 | 15.1 |
Insiders bought, 12 months
$4.8M
1 insider
Insiders sold, 12 months
$9.9M
4 insiders
Of sales under plans
100%
$9.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Bicara Therapeutics Inc. · BCAX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $17.48 a share, the company is worth $1.2B.
Source: SEC EDGAR XBRL filings (CIK 0002023658). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.